Metabolism Disorder TRIZ Cases

A pharmaceutical composition of insulin, citrate, zinc, and surfactants accelerates drug uptake from injection sites.

Isolating equine amniotic fluid-derived multipotent stem cells via centrifugation and specific culture media to produce homogeneous populations.

Tailoring linagliptin treatment to TCF7L2 genotypes resolves inadequate glycemic control and cardiovascular risks in type 2 diabetes.

ATPase inhibitory factor 1 peptide suppresses dietary intake while increasing muscle protein synthesis.

Methods inactivate amyloid-producing bacteria within the gut microbiota to reduce exposure to bacterial amyloid.

Merges four herbal extracts to resolve the trade-off between treatment simplicity and comprehensive health benefits.

Lactic acid bacteria modulate intestinal satiety signaling to reduce food intake and manage body weight.

Triple agonist peptides combine glucagon, GLP-1, and GIP receptor activities to preserve beta cells while achieving significant weight reduction.

A detection method using inactivated samples and labeled leptin to identify neutralizing antibodies.

A pet food composition incorporates specific metabolites to modulate cholesterol and lipoprotein levels in companion animals.

Segmenting the AMUC_1100 protein into smaller fragments resolves manufacturing difficulties while maintaining glucose tolerance improvement.

Targeted nutritional composition restores gut microbiota balance, addressing root causes of metabolic syndrome rather than merely treating symptoms.

Modified GIP analogs with specific amino acid substitutions and PEGylation activate dual receptors to sustain glucose-lowering effects while avoiding nausea.

Segmenting drug action to enterocytes limits systemic exposure, resolving side effects while treating obesity and dyslipidemia.

Albumin-binding FGF21 fusion proteins extend circulation time by leveraging endogenous albumin, reducing dosing frequency for metabolic disorders.

Modified peptide ligands for CB1 and CB2 receptors reduce metabolic disorders while avoiding psychiatric side effects from central nervous system penetration.

Alginic acid and a poorly soluble metal compound semi-solidify the liquid food composition in the stomach, preventing tube clogging during enteral feeding.

Modified glucagon analogs enhance GIP receptor activation potency to treat diabetes and obesity while maintaining native glucagon activity.

Codon-optimized nucleic acid molecules drive robust alpha-galactosidase A protein expression within cardiac tissue using a targeted recombinant adeno-associated virus vector system.

Small molecule modulators inhibit PCSK9 to preserve LDL receptor levels, lowering plasma cholesterol beyond statin therapy limits.

Oleic acid derivatives mimic natural fat taste by binding to CD36 and GPR120 receptors without adding caloric energy.

A lysine, zinc, and vitamin C supplement regimen reduces insulin resistance and prevents advanced glycation end product formation.

Ester-modified glycosides enhance oral bioavailability while maintaining SGLT inhibition activity.

Segmented polyketide synthase modules with modified KR and DH domains resolve the contradiction between high PUFA quantity and precise profile composition.

A modified glucagon derivative activates both GLP-1 and glucagon receptors to provide anti-obesity effects.

Selective extraction removes saccharides and heavy metals from Phaeodactylum tricornutum to achieve high purity fucoxanthin compositions.

A semi-permeable membrane combines porous and non-woven biocompatible polymer layers to encapsulate secreting cells.

A polyrotaxane composition threads cyclic molecules onto a linear polymer backbone to enhance cholesterol removal.

Converting plant sterols to bile acids eliminates toxins and contaminants found in animal-derived sources.

Specific lysine and branched-chain amino acid ratios increase lean muscle mass while preventing excess fat gain during rapid growth phases.

Segmenting the core and coating resolves manufacturing consistency issues while enabling rapid swelling and floatation for prolonged gastric retention.

Engineered bacterial CYP102A1 mutants overcome mammalian enzyme instability to produce stable 2-hydroxyl and 4-hydroxyl atorvastatin metabolites at scale.

Combining Lactobacillus fermentum GB-102 with natural killer cells suppresses weight gain through synergistic biological mechanisms.

Peptide hydrogel releases glucagon when glucose oxidase lowers local pH, preventing hypoglycemia.

Dde protecting groups block lysine residues to prevent multi-PEGylation side reactions and improve recovery yields.

A peptide sequence increases melanin synthesis by phosphorylating MITF transcription factors.

A cellular graft composition enriches hematopoietic stem cells and memory T cells while depleting naive conventional alpha beta-T cells.

Removing the connecting peptide restores receptor affinity while disulfide bonds maintain stability against fibrillation.

Ginseng berry extract suppresses TNF-α and NO generation to treat arteriosclerosis without adverse effects from synthetic drugs.

Segmenting the synthesis pathway into independent modules increases final yield and reproducibility compared to linear approaches.

CGPase enzymes break down cyanophycin into bioavailable dipeptides, resolving limited digestive tract utilization mechanisms.

Conjugating oxyntomodulin with polyethylene glycol via reversible linkers extends the peptide's biological half-life.

Segmenting the differentiation process into distinct stages maintains critical marker expression while minimizing NGN3 to improve efficiency.

Applying low, medium, and high frequency waves to raw water controls treatment effects while generating extranuclear electrons.

Nitro oleic acid binds PPAR-gamma receptors to lower blood glucose levels without causing weight gain or fluid retention.

Engineered protein variants boost GLP-1 inducibility through targeted amino acid substitutions.

Fully human monoclonal antibodies bind angiopoietin-like protein 8 to inhibit its activity, resolving the clinical applicability gap of non-human variants.

Solution phase synthesis replaces chromatography with crystallization to reduce purification time and raw material costs.